Biotechnology Assets (Spain) Performance
| BST Stock | 0.34 0.01 3.03% |
On a scale of 0 to 100, Biotechnology Assets holds a performance score of 3. The firm shows a Beta (market volatility) of -0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Biotechnology Assets are expected to decrease at a much lower rate. During the bear market, Biotechnology Assets is likely to outperform the market. Please check Biotechnology Assets' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Biotechnology Assets' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Biotechnology Assets SA are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady basic indicators, Biotechnology Assets exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Biotechnology |
Biotechnology Assets Relative Risk vs. Return Landscape
If you would invest 31.00 in Biotechnology Assets SA on August 28, 2024 and sell it today you would earn a total of 3.00 from holding Biotechnology Assets SA or generate 9.68% return on investment over 90 days. Biotechnology Assets SA is generating 0.2784% of daily returns assuming 5.6265% volatility of returns over the 90 days investment horizon. Simply put, 50% of all stocks have less volatile historical return distribution than Biotechnology Assets, and 95% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biotechnology Assets Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotechnology Assets' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Biotechnology Assets SA, and traders can use it to determine the average amount a Biotechnology Assets' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0495
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BST | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.63 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.28 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Biotechnology Assets is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotechnology Assets by adding it to a well-diversified portfolio.
Biotechnology Assets Fundamentals Growth
Biotechnology Stock prices reflect investors' perceptions of the future prospects and financial health of Biotechnology Assets, and Biotechnology Assets fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotechnology Stock performance.
| Return On Equity | -0.74 | |||
| Return On Asset | -0.0647 | |||
| Profit Margin | (0.92) % | |||
| Operating Margin | (0.63) % | |||
| Shares Outstanding | 48.35 M | |||
| Revenue | 3.28 M | |||
| EBITDA | (1.04 M) | |||
| Book Value Per Share | 0.1 X | |||
About Biotechnology Assets Performance
By analyzing Biotechnology Assets' fundamental ratios, stakeholders can gain valuable insights into Biotechnology Assets' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Biotechnology Assets has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Biotechnology Assets has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about Biotechnology Assets performance evaluation
Checking the ongoing alerts about Biotechnology Assets for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biotechnology Assets help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biotechnology Assets had very high historical volatility over the last 90 days | |
| Biotechnology Assets has some characteristics of a very speculative penny stock | |
| Biotechnology Assets has high likelihood to experience some financial distress in the next 2 years | |
| About 51.0% of the company shares are held by company insiders |
- Analyzing Biotechnology Assets' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotechnology Assets' stock is overvalued or undervalued compared to its peers.
- Examining Biotechnology Assets' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotechnology Assets' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotechnology Assets' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotechnology Assets' stock. These opinions can provide insight into Biotechnology Assets' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Biotechnology Stock analysis
When running Biotechnology Assets' price analysis, check to measure Biotechnology Assets' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotechnology Assets is operating at the current time. Most of Biotechnology Assets' value examination focuses on studying past and present price action to predict the probability of Biotechnology Assets' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotechnology Assets' price. Additionally, you may evaluate how the addition of Biotechnology Assets to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |